Researchers at Carnegie Mellon University (CMU) are spearheading a revolutionary project aimed at early cancer detection. With a substantial federal funding of up to $26.7 million from the Advanced Research Projects Agency for Health (ARPA-H), this initiative strives to identify over 30 types of Stage 1 cancer from the comfort of patients’ homes.
Development of the At-Home Test
The proposed screening test involves a multistep process. Initially, patients will swallow a bioengineered pill containing tumor sensors. These sensors are activated by low oxygen, acidity, and lactate levels, which are indicative of cancer. Once triggered, they release signals that indicate tumor presence and its tissue origin, subsequently excreted in urine.
In the next step, patients will perform a urine test using a simple device that determines tumor presence and its location. Results will be shared via smartphone with medical professionals for further assessment and treatment options.
Leadership and Collaboration
Professor Rebecca Taylor, a Mechanical Engineering expert at CMU, is the principal investigator of this project. She emphasizes the potential it has to save lives and reduce healthcare costs. Alongside her, Burak Ozdoganlar, also a mechanical engineering professor, is co-leading the research.
Aiming for Impact in 2026
The project commenced in October 2025, focusing on developing various molecular sensors. The research team includes seven institutions, each bringing specialized knowledge to enhance the project.
Goals of Early Cancer Detection
The primary objective is to allow doctors to treat diseases when they are highly treatable. Early detection could revolutionize cancer treatment and increase the quality of life for many patients. Regular testing could provide peace of mind, highlighting the absence of tumors or identifying treatable ones.
- Potential for at-home detection could reach millions, aiding families affected by cancer.
- Trust in the device is crucial for user adoption.
- Solutions must be reliable, user-friendly, and low-cost.
Building Trust and Ensuring Affordability
Establishing user trust is paramount. The design must foster reliability and affordability. Researchers are collaborating with UPMC Hillman Cancer Center to survey community preferences and price points. ARPA-H has noted that projects should aim for a retail price around $100, a challenge the team is optimistic about overcoming.
This innovative approach not only seeks to transform cancer detection but could also set a new standard in medical technology. By integrating molecular components with user-friendly interfaces, CMU is paving the way for a promising future in early cancer detection, making a significant difference in patients’ lives.
